Meanwhile, normal ABL1 protein was found to act as a tumor suppressor when co-expressed with BCR-ABL, while loss of expression of normal ABL1 results in higher aggressiveness of the disease and reduced sensitivity to Imatinib-like TKIs, although we are not sure which isoform is primarily responsible for this effect either77,78. This evidence concerns the gene BCR and neoplasm.